For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …

In 2019, the Japanese Circulation Society published 2 guidelines in the field of coronary
artery disease (CAD):(1) a guideline for acute coronary syndrome (ACS) that integrated …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Objective To assess the risks and benefits of P2Y 12 inhibitor monotherapy compared with
dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' …

Background Polymer-free drug-coated stents provide superior clinical outcomes to bare-
metal stents in patients at high bleeding risk who undergo percutaneous coronary …

Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …

A growing number of patients undergoing percutaneous coronary intervention (PCI) with
stent implantation also have atrial fibrillation. This poses challenges for their optimal …

Aim To assess the effects of 1-or≥ 3-month dual antiplatelet therapy (DAPT) in high
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …

Since its introduction in 1977, percutaneous coronary intervention has become one of the
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …

Background: Recently, the Academic Research Consortium for High Bleeding Risk (ARC-
HBR) has been proposed to standardize the definition of HBR, which was arbitrarily defined …